Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 99

The DOI matches its Crossref record.

Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections

Eljaaly, Khalid, Alharbi, Aisha, Alshehri, Samah, Ortwine, Jessica K., Pogue, Jason M.·2019·Drugs

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-019-1054-3

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 54

  1. Doi Y, Bonomo RA, Hooper DC, Kaye KS, Johnson JR, Clancy CJ, et al. Gram-negative bacterial infections: Research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis. 2017;1:30–5. · DOI
  2. Kunz AN, Brook I. Emerging resistant Gram-negative aerobic bacilli in hospital-acquired infections. Chemotherapy. 2010;56:492–500. · DOI
  3. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–917. · DOI · Paper page
  4. Van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al. Colsitin versus ceftazidime-avibactam in the treatment of infections due to carbapebem-resistant Enterobacteriacea. Clin Infect Dis. 2018;66(2):163–71. · DOI · Paper page
  5. Wunderlink R, Giamarellos-Bourboulis E, Rahav G, Mathers A, Bassetti M, Solomkin J, et al. Meropenem-vaborbactam vs. best available therapy for carbapenem-resistant Enterobacteriacea infections in Tango II: primary outcomes by site of infection. Open Forum Infect Dis. 2017;4:S536–S537. · doi:10.1093/ofid/ofx163.1397
  6. Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101–17. · DOI · Paper page
  7. Shields RK, Potoski BA, Haidar H, Hao B, Doi Y, Chen L, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. · DOI · Paper page
  8. Dozzo P, Moser HE. New aminoglycoside antibiotics. Expert Opin Ther Patents. 2010;20(10):1321–41. · DOI
  9. Cloutier DJ, Miller LG, Komirenko AS, Cebrik D, Krause K, Keepers T, et al. Plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results of the EPIC study. In: 27th European congress of clinical microbiology and infectious diseases, Austria; 2017. · doi:10.1093/ofid/ofx163.1385
  10. Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules. 2017;22(12):2267. · DOI · Paper page
  11. Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol. 2010;13(5):565–73. · DOI
  12. Karpiuk I, Tyski S. Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials. Przegl Epidemiol. 2015;69(4):723–729.
  13. Syue LS, Chen YH, Ko WC, Hsueh PR. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int J Antimicrob Agents. 2016;47(4):250–8. · doi:10.1016/j.ijantimicag.2015.12.021
  14. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43(4):727–37. · DOI · Paper page
  15. Denervaud-Tendon V, Poirel L, Connolly LE, Krause KM, Nordmann P. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. Antimicrob Agents Chemother. 2017;72(10):2787–91. · DOI
  16. Houghton JL, Green KD, Chen W, Garneau-Tsodikova S. The future of aminoglycosides: the end or renaissance? ChemBioChem. 2010;11(7):880–902. · DOI · Paper page
  17. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin N Am. 2016;30(2):523–537. · DOI · Paper page
  18. Castanheira M, Mendes RE, Streit JM, Flamm RK. Activity of plazomicin and comparator agents tested against Gram-negative and-positive clinical isolates collected in US hospitals during 2015. Open Forum Infect Dis. 2016;3(supp_1):1822. · doi:10.1093/ofid/ofw172.1370
  19. Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011;1241(1):122–52. · DOI
  20. Landman D, Kelly P, Bäcker M, Babu E, Shah N, Bratu, et al. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J Antimicrob Chemother. 2011;66(2):332–4. · doi:10.1093/jac/dkq459
  21. Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents chemother. 2009;53(10):4504–7. · DOI
  22. Biedenbach DJ, Jones RN, Armstrong ES, Aggen JB, Miller GH. Activity of ACHN-490 against complicated urinary tract infection (cUTI) pathogens from the United States and Europe. In: Poster presented at 49th interscience conference on antimicrobial agents and chemotherapy; 12–15 Sep 2009; San Francisco.
  23. Jones RN, Armstrong ES, Aggen JB, Biedenbach DJ, Miller GH. Antimicrobial activity of ACHN-490, a neoglycoside, tested against a contemporary collection of clinical isolates including problematic antimicrobial-resistant phenotypes. In: Poster presented at 49th interscience conference on antimicrobial agents and chemotherapy; 12–15 Sep 2009, San Francisco.
  24. Landman D, Babu E, Shah N, Kelly P, Bäcker M, Bratu S, et al. Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City. J Antimicrob Chemother. 2010;65(10):2123–7. · doi:10.1093/jac/dkq278
  25. Georgescu C, Martin DA, Bratu S, Quale J, Landman D. Activity of ACHN-490, a novel neoglycoside antibiotic, against contemporary gram-negative clinical isolates from Brooklyn, NY hospitals. In: Poster presented at 49th interscience conference on antimicrobial agents and chemotherapy, 12–15 Sep 2009, San Francisco.
  26. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011;66(1):48–53. · doi:10.1093/jac/dkq408
  27. Badal R, Lob S, Hackel M, Bouchillon S, Hoban D, Armstrong D. In vitro activity of ACHN-490 against recent respiratory tract pathogens. In: Poster presented at 51st interscience conference on antimicrobial agents and chemotherapy, 17–20 Sep 2011, Chicago.
  28. Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky AJ, et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother. 2014;58(5):2554–63. · DOI
  29. Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobater spp. from Athens, Greece. J Chemother. 2012;24(4):191–4. · DOI
  30. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother. 2014;58(8):4443–51. · doi:10.1128/aac.00099-14
  31. Alkroud AA, Shields RK, Clancy CJ, Press EG, Hao B, Nguyen MH. Plazomicin activity against carbapenem non-susceptible Enterobacter strains that exhibit various levels of resistance to aminoglycosides. In: Poster presented at 55th interscience conference on antimicrobial agents and chemotherapy, 18–21 Sep 2015, San Diego.
  32. Rodriguez-Avial I, Pena I, Picazo JJ, Rodríguez-Avial C, Culebras E. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46(6):616–21. · doi:10.1016/j.ijantimicag.2015.07.021
  33. Lopez-Diaz MC, Culebras E, Rodriguez-Avial I, Rios E, Viñuela-Prieto JM, Picazo JJ, et al. Plazomicin activity against 346 extended-spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates in relation to aminoglycoside-modifying enzymes. Antimicrob Agents Chemother. 2017;61(2):e02454–516.
  34. Martins AF, Bail L, Ito CAS, da Silva Nogueira K, Dalmolin TV, Martins AS, et al. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers. Diagn Microbiol Infect Dis. 2018;90(3):228–32. · DOI
  35. Castanheira M, Doyle TB, Serio AW, Krause KM, Streit JM, Flamm RK. In vitro activity of plazomicin and comparator agents against urinary tract infection isolates from the United States and Europe. In: Poster presented at 2nd American Society for Microbiology Microbe, 1–5 June 2017, New Orleans. · doi:10.1093/ofid/ofy210.1176
  36. Castanheira M, Streit JM, Deshpande LM, Mendes RE, Flamm RK. Activity of plazomicin and comparator agents tested against recent clinical isolates collected in Asia–Pacific, Europe, and Latin America. In: Poster presented at 27th European congress of clinical microbiology and infectious diseases, 22–25 Apr 2017; Vienna. · doi:10.26226/morressier.56d6be7ad462b80296c97c80
  37. Olsen SC, Carlson SA. In vitro bactericidal activity of aminoglycosides, including the next-generation drug plazomicin, against Brucella spp. Int J Antimicrob Agents. 2015;45(1):76–8. · doi:10.1016/j.ijantimicag.2014.09.011
  38. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother. 2010;54(11):4636–42. · DOI · Paper page
  39. Tenover FC, Tickler I, Armstrong ES, Kubo A, Lopez S, Persing DH, et al. Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int J Antimicrob Agents. 2011;38(4):352–4. · DOI
  40. Lopez Diaz MC, Rios E, Rodriguez-Avial I, Simaluiza RJ, Picazo JJ, Culebras E. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents. Int J Antimicrob Agents. 2017;50(2):191–6. · DOI
  41. Cass RT, Brooks CD, Havrilla, NA, Tack K, Borin M, Young D, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother. 2011;00624–11. · doi:10.1128/aac.00624-11
  42. Huy PTB, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest. 1986;77(5):1492–1500.‏ · DOI · Paper page
  43. Israel KS, Welles JS, Black HR. Aspects of the pharmacology and toxicology of tobramycin in animals and humans. J Infect Dis. 1976;134(1):97–103. · doi:10.1093/infdis/134.supplement_1.s97
  44. Matsumoto H, Ochiai K, Nakajima A, Matsuzaki M. Absorption, excretion and distribution of amikacin following intravenous drip infusion. Intravenous drip infusion, one shot intravenous injection and intramuscular administration of amikacin in dogs, rabbits and rats. Jpn J Antibiot. 1982;35(8):2034–2046.‏
  45. Louie A, Fikes S, Liu W, VanScoy B, Cirz R, Drusano G. Pharmacodynamics of plazomicin in a neutropenic murine pneumonia model against Klebsiella pneumoniae (Kpn). In: Abstract presented at 52nd interscience conference on antimicrobial agents and chemotherapy, 9–12 Sep 2012; San Francisco.
  46. Reyes N, Aggen JB, Kostrub CF. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob Agents Chemother. 2011;55(4):1728–33. · doi:10.1128/aac.00862-10
  47. Bruse K, Mega W, Overheim K, Cirz R, Cass R, Valderas M, et al. Telemetry used to determine efficacy of intravenous Plazomicin against inhaled tularemia in cynomolgus macaques (CM). J Pharmacol Toxicol Methods. 2014;70(3):334. · doi:10.1016/j.vascn.2014.03.088
  48. Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, et al. Interaction of drug-and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis. 2014;210(8):1319–24. · doi:10.1093/infdis/jiu237
  49. Layton RC, Brasel T, Gigliotti A, Cirz R, Robbins N, Kurhanewicz S, et al. Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation. J Med Primatol. 2011;40(1):6–17. · doi:10.1111/j.1600-0684.2010.00443.x
  50. Abdelraouf K, Kim A, Krause KM, Nicloau DP. In vivo efficacy of plazomicin alone or in combination with meropenem or tigecycline against Enterobacteriaceae isolates exhibiting various resistance mechanisms in an immunocompetent murine septicemia model. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.01074-18 . · DOI
  51. Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. Efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis: a multicenter, randomized, double-blind, phase 2 study. Antimicrob. Agents Chemother. 2018;01989–17. · DOI
  52. Riddle V, Mason J, Cebrik D, Kostrub C, Fong L, Hillan KJ. The effect of plazomicin injection on the QT/QTc interval in healthy volunteers (abstract no. A017f plus poster). In: 53rd interscience conference on antimicrobial agents and chemotherapy; 2013; San Francisco.
  53. Havrilla NA, Brooks CD, Cass RT, Tack KJ, Bruss J B. Pharmacokinetics (PK) and safety of ACHN-490 injection administered intravenously for five days in healthy human subjects (abstract no. A1658 plus poster). In: 50th interscience conference on antimicrobial agents and chemotherapy; 2010; Boston.
  54. Cass RT, McKinnell JV, Xie B, Karr DE, Schmidt DE. Pharmacokinetics of the novel neoglycoside ACHN-490 in mouse, rat, and dog (abstract no. F1846 plus poster). In: 49th interscience conference on antimicrobial agents and chemotherapy; 2009; San Francisco.

Cited by

See all 99

Metadata

Authors
Eljaaly, K., Alharbi, A., Alshehri, S., Ortwine, J. K., & Pogue, J. M.
Venue
Drugs
Published
2019-02
Volume
79
Issue
3
Pages
243-269
ISSN
  • 0012-6667
  • 1179-1950
Cited by
99
References
0
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. https://app.cochat.ai/papers/10.1007/s40265-019-1054-3
The paper
Eljaaly, K., Alharbi, A., Alshehri, S., Ortwine, J. K., & Pogue, J. M. (2019). Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Drugs. https://doi.org/10.1007/s40265-019-1054-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.